← Back to Cancer ScreeningFDA approved (CDx)
Tempus
Cancer patients wanting AI-matched treatment options
Variable
Test Performance
Sensitivity
N/A
Specificity
N/A
Detection Method
Genomic + AI
Turnaround
10-14 days
Key Features
Largest genomic database • AI-powered insights • Clinical trial matching • Liquid + tissue options
Who It's For
Important Notes
Combines genomic testing with AI for treatment recommendations. xT CDx is an FDA-approved 648-gene tissue assay;the FDA approved the tumor-only indication in May 2026, making Tempus the first lab with CDx approval for both tumor-only and tumor-normal comprehensive genomic profiling. Liquid biopsy options:xF (105 genes) and xF+ (523 genes), 7-9 day turnaround.